Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2005
04/06/2005CN1602960A Mixture for preventing and treating metabolic syndrome like cerebrovascular and cardiovascular disease
04/06/2005CN1602959A Nutrient product for enhancing immunity, preventing cancer and prolonging life of cancer patient and its preparing method
04/06/2005CN1602880A Method for inhibitting bone resorption
04/06/2005CN1602879A Method for inhibitting bone resorption
04/06/2005CN1602841A Immuno-modulatory agents administration form for whole body or local immunity disorder
04/06/2005CN1195849C APPIL-a novel protein with growth effects
04/06/2005CN1195788C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
04/06/2005CN1195775C Glucoprotein having inhibitory activity to pyroric spirillar colonization
04/06/2005CN1195755C Pyrrolo [2, 3-d] pyrimidine compounds
04/06/2005CN1195547C Preventives / remedies for glaucoma
04/06/2005CN1195543C Method for administering monomeric insulin analogs
04/06/2005CN1195525C Antitumor agents comprising silicon and nitrogen containing compounds as the principal agent
04/06/2005CN1195515C Amide derivatives for antiangiogenic and/or antitumorgenic use
04/06/2005CN1195511C The use of fumaric acid derivatives in transplant medicine
04/06/2005CN1195508C Use of inhibitors of sodium-hydrogen pump for production of medicament for decreaing undesired effects of substances on heart
04/06/2005CN1195504C Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
04/06/2005CN1195497C Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonist and method for preparing the same
04/06/2005CN1195494C Oral liquid mucoadhesive compositions
04/05/2005US6875886 Modified PSMA ligands and uses related thereto
04/05/2005US6875846 Heterologous polypeptide of the TNF family
04/05/2005US6875843 Reducing the rate of islet cell infiltration by lymphocytes in a diabetes-susceptible mammal by administering a gonadotropin-releasing hormone antagonist.
04/05/2005US6875789 Pyrazole-derived kinase inhibitors and uses thereof
04/05/2005US6875767 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
04/05/2005US6875749 Methods of facilitating vascular growth
04/05/2005US6875745 Synergistic mixture of lapachone and taxane; anticancer, antitumor agents
04/05/2005US6875740 Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens
04/05/2005US6875736 Methods for identifying RNA binding compounds
04/05/2005US6875597 Comprises nucleotide sequences coding sulfotransferase for identifying modulators and designing drug delivery systems
04/05/2005US6875451 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
04/05/2005US6875439 Controlling drug resistance; intensify therapy; increas accumulation in cell
04/05/2005US6875435 In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent
04/05/2005US6875422 Oral treatment/care agent
04/05/2005CA2276146C Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants
03/2005
03/31/2005WO2005028504A2 Regulation of tissue mineralization and phosphate met abolism by asarm peptides
03/31/2005WO2005028474A2 Pyrazoloquinoline derivatives as chk-1 inhibitors
03/31/2005WO2005027975A1 Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors
03/31/2005WO2005027974A1 Anti cancer combinations comprising a cox-2 inhibitor
03/31/2005WO2005027973A2 Combinations of a vegf receptor inhibitor with other therapeutic agents
03/31/2005WO2005027972A2 Combination of a vegf receptor inhibitor with a chemotherapeutic agent
03/31/2005WO2005027971A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
03/31/2005WO2005027970A1 Drugs for treating cancer
03/31/2005WO2005027967A1 Medicinal composition
03/31/2005WO2005027951A1 Method for controlling angiogenesis in animals
03/31/2005WO2005027950A1 Eye nutritional supplement
03/31/2005WO2005027948A1 Powdery composition for use as a laxative
03/31/2005WO2005027936A2 Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
03/31/2005WO2005027931A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
03/31/2005WO2005027924A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005WO2005027923A1 Use of vitamin d3 analogue for the treatment of benign prostatic hyperplasia
03/31/2005WO2005027907A1 Use of chk1 inhibitors to control cell proliferation
03/31/2005WO2005027905A1 Pharmaceutical compositions for the treatment of organophosphate poisoning
03/31/2005WO2005027902A1 MODULATORS OF Cdk9 AS A THERAPEUTIC TARGET IN CARDIAC HYPERTROPHY
03/31/2005WO2005027896A1 Concurrent drugs
03/31/2005WO2005027895A2 Thyroid hormone analogs and methods of use in angiogenesis
03/31/2005WO2005027882A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/31/2005WO2005027877A1 Antibiotic product, use and formulation thereof
03/31/2005WO2005027874A2 Solid or semi-solid therapeutic formulations
03/31/2005WO2005027855A2 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
03/31/2005WO2005027841A2 Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease
03/31/2005WO2005027839A2 Methods and reagents for the treatment of immunoinflammatory disorders
03/31/2005WO2005027831A2 Modulators of p-selectin glycoprotein ligand 1
03/31/2005WO2005027808A1 Calcium zeolite hemostatic agent
03/31/2005WO2005027663A2 Compositions comprising oligosaccharides
03/31/2005WO2005027661A1 Compositions for the treatment and prevention of diabetes mellitus
03/31/2005WO2005011636A3 Spray drying processes for forming solid amorphous dispersions of drugs and polymers
03/31/2005WO2005009143A3 Novel fluorinated food products and the use thereof for harmonious osseous development
03/31/2005WO2004105688A3 Bactericidal composition and associated method
03/31/2005WO2004098617A3 Controlled release composition containing a strontium salt
03/31/2005WO2004076369A3 Antimicrobial active borosilicate glass
03/31/2005WO2004075856A3 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
03/31/2005WO2004073606A3 Sulfonamide derivatives as ppar modulators
03/31/2005WO2004064734A3 Combination therapies for the treatment of cancer
03/31/2005WO2004032876A3 Deguelin as a chemopreventive agent for lung cancer
03/31/2005WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp
03/31/2005WO2003038060A3 Small molecule inhibitors targeted at bcl-2
03/31/2005WO2003018756A3 Methods for preparing purified prostaglandin e synthase
03/31/2005WO2002099054A3 Hccss as modifiers of the p53 pathway and methods of use
03/31/2005WO2002067968A9 14-3-3 binding molecules as sensitizers for anticancer therapies
03/31/2005US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration
03/31/2005US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070699 Nucleotide sequences coding low density lipoprotein receptor-related protein 5 for use as tools in diagnosis and treatment of osteoporosis; high bone mass and bone disorders
03/31/2005US20050070612 Monitoring cell proliferation of prostate cancer cells; incubation with quercetin; monitoring adjustment of gene expression
03/31/2005US20050070604 Vaginal cleanser; inhibit production of exotoxins from grampositive bacteria
03/31/2005US20050070595 Complex of trioxane with iron compound
03/31/2005US20050070594 Use of angiotensin II receptor antagonists
03/31/2005US20050070577 Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
03/31/2005US20050070553 Pharmaceutical composition comprising an alpha-glucosidase inhibitor and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/31/2005US20050070524 Diagnosi of central nervous systemdisease; administering enzyme inhibitor
03/31/2005US20050070516 As-needed administration of an androgenic agent to enhance female desire and responsiveness
03/31/2005US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid
03/31/2005US20050070512 Pharmaceutical composition and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist
03/31/2005US20050070510 Tetracycline compound of given formula, an antifungal agent such as amphotericin B and a carrier; treating fungal infections
03/31/2005US20050070498 Enteral formulation
03/31/2005US20050070491 Immunostimulatory nucleic acid molecules
03/31/2005US20050070489 Adverse side effect reduction of antiviral therapy by interrupting antiviral treatment after HIV levels are suppressed, administering double stranded RNA (dsRNA) and resuming antiviral agent treatment when HIV values increase; increases the time to HIV rebound after stopping the antiviral agent therapy
03/31/2005US20050070487 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
03/31/2005US20050070482 Peptides substituted with a functional group that reacts with an active site residue of the targeted protease, e.g., Cyclohexylglycine BoroAla, and compounds that can hydrolyzed to produce them; improved specificity for regulating glucose metabolism
1 ... 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 ... 1151